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Non-small cell lung cancer (NSCLC) has a relatively poor prognosis and is a leading 
cause of cancer death worldwide. A substantial proportion of NSCLC patients suffer a 
recurrence following curative tumor resection, even when they have early stage disease. 
Molecular markers that are able to predict patient prognosis after surgery are therefore 
of clinical relevance, especially for early stage NSCLC. Herein, we report that 
methylation of long interspersed nuclear element 1 (LINE-1) in tumor DNA shows 
promise as a prognostic factor for stage IA NSCLC. Analysis of 364 NSCLC cases 
revealed that patients with LINE-1 hypomethylation had significantly shorter survival 
compared to those with LINE-1 hypermethylation. The survival difference according to 
LINE-1 methylation status was greatest in patients with stage IA disease. These results 
indicate that LINE-1 tumor methylation level may help to select early stage NSCLC 




Purpose: Global hypomethylation and the hypermethylation of gene promoter regions 
are common events in tumor DNA. The aim of this study was to evaluate the prognostic 
significance of both global hypomethylation and gene promoter hypermethylation in 
DNA from non-small cell lung cancer (NSCLC).  
Experimental Design: Genomic DNA was obtained from tumor tissue of 379 NSCLC 
patients who underwent surgery. Methylation levels were measured by real-time PCR 
following bisulfite modification of DNA and were correlated with clinicopathological 
parameters and patient prognosis. Methylation of long interspersed nuclear element 1 
(LINE-1) was used as a surrogate marker for global methylation. Hypermethylation of 
the APC, CDH13 and RASSF1 promoter regions was also evaluated. 
Results: Tumor tissue showed significantly higher CDH13 and RASSF1 methylation 
levels compared to normal lung tissue, but lower LINE-1 methylation levels. APC, 
RASSF1 and LINE-1 methylation levels were significant prognostic factors in 
univariate analysis of an initial cohort of 234 cases. APC and LINE-1 methylation 
remained significant prognostic factors in multivariate analysis that included age, 
gender, smoking history, histological type and pathological stage. LINE-1 methylation 
showed marginally significant prognostic value in stage IA and IB disease. Expansion of 
the study cohort to 364 cases revealed that LINE-1 methylation had significant 
prognostic value for stage IA NSCLC patients in multivariate analysis. 
Conclusions: LINE-1 hypomethylation was an independent marker of poor prognosis in 
stage IA NSCLC. Validation of this finding in additional tumor cohorts could have 
clinical relevance for the management of early stage NSCLC. (243 words)
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Introduction 
Despite recent advances in our understanding of the molecular mechanisms of 
carcinogenesis and in the use of multi-modal cancer therapy, lung cancer remains one of 
the major causes of cancer-related deaths worldwide. Surgery is still the major 
treatment for non-small cell lung cancer (NSCLC). Even in patients with pathological 
stage I disease, the cumulative 5-year survival rate is around 60% (1, 2). A growing body 
of clinical evidence indicates that adjuvant chemotherapy after surgery confers a 
survival benefit for NSCLC patients (3, 4). Therefore, accurate prognostic markers are 
required to help select the optimal treatment modality for individual lung cancer 
patients, including the use of adjuvant chemotherapy. 
Aberrant methylation of CpG di-nucleotides is a commonly observed epigenetic 
modification in human cancer (5). The two phenomena of global genomic DNA 
hypomethylation and hypermethylation of gene promoter regions occur in parallel and 
are observed in a wide variety of cancer types (6, 7). Hypermethylation of gene 
promoters is often associated with transcriptional silencing of tumor suppressors. 
Numerous studies have suggested possible clinical uses of promoter hypermethylation 
as markers of early diagnosis (8-11) and as predictors of patient outcome (12-15). 
However, there is no consensus regarding the genes to be analyzed for specific clinical 
applications. We previously reported that p16 methylation was a candidate prognostic 
marker in NSCLC patients (16). A recent study also showed that APC, CDH13 and 
RASSF1 methylation were promising markers for predicting the early recurrence of 
lung cancer (17). On the other hand, the molecular mechanisms that underlie global 
DNA hypomethylation in tumorigenesis are poorly understood, although an 
involvement with genomic instability has long been suggested (18, 19). Only a few 
studies have analyzed global hypomethylation in primary cancers with the aim of 
exploring its clinical importance as a molecular marker (20-22). 
Long interspersed nuclear element 1 (LINE-1) represents a family of 
non-long-terminal-repeat retroposons that are interspersed throughout genomic DNA 
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and comprise about 18% of the human genome (23, 24). Because of their high frequency 
in the genome, LINE-1 methylation serves as a useful surrogate marker of global 
methylation (25). LINE-1 is heavily methylated in normal human tissues, however loss 
of methylation is consistently observed in human cancers (26, 27) and accounts for a 
substantial proportion of the genomic hypomethylation observed in this disease. Most 
LINE-1 sequences in the human genome are truncated in the 5’ region or mutated, 
making transposition impotent (23). However, about 100 copies of full length LINE-1 
sequence are present and have the ability to transpose (28, 29). Hypomethylation in the 
promoter region of potent LINE-1 sequence causes transcriptional activation of LINE-1, 
resulting in transposition of the retro-element and chromosomal alteration. LINE-1 
methylation status may therefore be a key factor linking global hypomethylation with 
genomic instability (30, 31). The association between LINE-1 methylation and genomic 
instability also suggests that it may be a good prognostic marker in cancer, since 
previous studies have reported associations between genomic instability and the 
outcome of cancer patients (32-34). 
Following our earlier demonstration of prognostic value for p16 methylation in 
NSCLC (16), the aim of the present study was to evaluate other candidate methylation 
markers as predictors of patient outcome. Methylation levels of the APC, CDH13 and 
RASSF1 gene promoters and of LINE-1 were quantitatively assessed in a large series of 
unselected NSCLC and matching normal lung tissues. These were analyzed in relation 
to clinicopathological features and to patient outcomes. In addition, we investigated loss 
of heterozygosity (LOH) in a subset of tumor samples in order to correlate LINE-1 
hypomethylation with genomic instability. 
 
Materials and Methods 
Patients and tissue samples. Tumor samples were obtained from a consecutive series of 
379 NSCLC patients who underwent surgery at Kanazawa University Hospital. 
Corresponding normal lung tissues were available for 333 of these patients. The 
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patients comprised 248 males and 131 females and ranged in age from 13-83 years 
(mean 64.3 years). Smoking history was obtained from the health interview 
questionnaire. Current and former smokers were classified as “smoker” and never 
smokers as “non-smoker”. All tissue samples were fixed in formalin and embedded in 
paraffin followed by histological diagnosis with hematoxylin-eosin staining. Tissues for 
DNA isolation were dissected manually from formalin-fixed and paraffin-embedded 
(FFPE) tissue sections (10 μm thickness). After deparaffinization using xylene and 
ethanol, genomic DNA was isolated using a QIAamp DNA mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. Approval for this project was 
obtained from the Kanazawa University Medical Ethics Committee. 
Quantitative methylation analysis of LINE-1 and gene promoter regions. DNA samples 
were subjected to bisulfite treatment using a CpGenome DNA Modification Kit 
(Chemicon, Temecula, CA) according to the manufacturer’s protocol. LINE-1 
methylation was measured using a methylation-specific real-time PCR assay as 
previously described (27). Real-time reactions for unmethylated and methylated LINE-1 
sequences were performed simultaneously in a 96-well plate. The percentage of 
methylated LINE-1 was calculated using the formula: 100 x methylated 
reaction/(unmethylated reaction + methylated reaction). The level of promoter 
methylation for APC, CDH13 and RASSF1 was measured by MethyLight assay as 
described previously (35, 36). The amount of ALU product measured by 
methylation-independent reaction was used for normalization. Methylation values were 
calculated using CpG methylase (M.SssI)-treated genomic DNA as the constant 
reference sample and were expressed as a percentage of the methylated reference 
(PMR). Oligonucleotide sequences for primers and probes were as described previously 
(37). Real-time PCR was conducted using the ABI-PRISM 7900 Sequence Detection 
System (Applied Biosystems, Foster, CA) and Premix Ex Taq (TaKaRa Bio, Otsu, Japan) 
following the protocol provided by the manufacturer. 
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Loss of heterozygosity. LOH status was investigated by screening 3 microsatellite loci 
that flank the APC, P16 and P53 loci. DNA from tumor and matching normal tissues of 
51 patients selected randomly was amplified with fluorescence-labeled primers. The 
PCR conditions were 35 cycles of 98℃, 20 seconds and 60℃, 60 seconds. The sets of 
primers used for specific amplification of the microsatellite sequences were: 
D5S346 forward primer, FAM-ACTCACTCTAGTGATAAATCGGG 
D5S346 reverse primer, AGCAGATAAGACAGTATTACTAGTT 
D9S942 forward primer, FAM-GCAAGATTCCAAACAGTA 
D9S942 reverse primer, CTCATCCTGCGGAAACCATT 
TP53 forward primer, FAM-TGCCCCATTCCCCTTTCCCT 
TP53 reverse primer, GATACTATTCAGCCCGAGTT 
LOH analysis was conducted by capillary electrophoresis using the ABI-PRISM 310 
Sequence Detection System and GeneMapper software version 4.0 following the 
protocol provided by the manufacturer (Applied Biosystems, Foster, CA). Allelic 
imbalance was calculated using the formula: (peak of allele 1 in tumor sample/peak of 
allele 2 in tumor sample)/(peak of allele 1 in normal sample/peak of allele 2 in normal 
sample). Allelic imbalance values that were >1.35 or <0.67 were considered to represent 
LOH. 
Statistical analysis. Associations between gene methylation levels and 
clinicopathological variables were analyzed by the Mann-Whitney U-test or the 
Kruskal-Wallis test. The statistical significance of methylation status as a prognostic 
factor was evaluated using the Cox proportional hazard regression model. The 
cumulative survival rate was calculated by the Kaplan-Meier method and statistical 
significance was analyzed by Log-rank test. All statistical analyses were carried out 





DNA methylation levels and clinicopathological features of NSCLC 
Methylation levels were analyzed in an initial cohort of 246 matched normal and tumor 
tissues. DNA extraction was unsuccessful in 31 normal tissues, resulting in a total of 
215 normal and 246 tumor tissues that were analyzed for methylation. CDH13 and 
RASSF1 methylation levels were significantly higher in tumor compared to normal 
tissue, whereas LINE-1 methylation was significantly lower (Fig. 1). APC methylation 
levels were not significantly different between tumor and normal tissues. 
Associations between methylation and clinicopathological features are shown in 
Table 1 and in Supplementary Table 1. APC methylation was significantly lower in 
squamous cell carcinoma compared to other histological types. RASSF1 methylation 
was significantly higher in tumors from older patients. Striking associations were 
observed between LINE-1 methylation and all clinicopathological features examined. 
The observed associations of LINE-1 hypomethylation with male gender, smoking and 
squamous cell histology are likely to be due to close associations between these 
clinicopathological variables (gender and smoking history, p<0.0001; gender and tumor 
histology, p<0.0001; smoking history and tumor histology, p<0.0001; chi-square test). 
Tumor tissue DNA methylation levels and patient prognosis  
Survival information was available for 235 patients from the initial cohort (median 
follow up time 45.5 months, range 2-149 months). In exploratory analysis, a variety of 
cut-off values were set for methylation and the patients classified accordingly into 
hyper- or hypomethylated groups for each gene. The survival of these patient groups 
was compared using the Kaplan-Meier method and the Log-rank test. The relationships 
between methylation cut-off values and p-values (Log-rank test) are shown in the left 
panels of Fig. 2 for each methylation marker. CDH13 methylation levels in tumor tissue 
did not show prognostic significance with any of the cut-off values used (left panel of Fig. 
2B). In contrast, APC, RASSF1 and LINE-1 methylation levels were significantly 
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associated with patient survival (left panels of Fig. 2A, C and D, respectively). The 
strongest associations were observed using cut-off values of 15 PMR for APC, 65 PMR 
for RASSF1 and 90% methylation for LINE-1. These cut-off values were used for 
Kaplan-Meier survival analysis (right panel of Fig.2) and for multivariate analyses. 
Hypermethylation of APC and RASSF1 in tumor tissue was a marker of poor prognosis 
(right panels of Fig. 2A and C, respectively), whereas hypomethylation of LINE-1 was 
associated with poor prognosis (right panel of Fig. 2D). 
 Multivariate analysis was used to determine whether APC, RASSF1 and LINE-1 
methylation were associated with patient prognosis independently of other 
clinicopathological variables. The analysis included the variables of age, gender, 
smoking history, histological type, pathological stage and methylation status defined by 
the above-mentioned cut-off values. RASSF1 methylation status was not a significant 
prognostic factor in multivariate analysis, whereas APC and LINE-1 methylation 
remained significant together with the factors of age, gender and pathological stage 
(Table 2).  
Although APC and LINE-1 methylation levels were independently associated with 
the patients’ prognosis in the multivariate analysis, the most significant prognostic 
factor was pathological stages (P<0.0001) (Table 2). Therefore, these methylation 
markers have less clinical value in predicting the prognosis of the NSCLC patients with 
all pathological stages. To clarify the clinical value of APC and LINE-1 methylation 
levels, the results were reanalyzed according to different stage sub-groups. APC 
methylation stratified according to a cut-off value of 15 PMR showed no prognostic 
significance in any of the stages (IA, P=0.22; IB, P=0.97; II, P=0.20; III, P=0.22). 
Although not reaching statistical significance, trends for prognostic value were observed 
for LINE-1 methylation in stage IA (P=0.058) and IB (P=0.053) patients. These results 
suggest that APC and LINE-1 methylation may be novel prognostic factors for NSCLC. 
However, it is unclear whether they are of clinical value complementing pathological 
stage system and whether LINE-1 methylation is a significant prognostic factor in early 
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stage NSCLC. 
LINE-1 methylation as a prognostic factor in stage IA NSCLC 
To examine whether LINE-1 methylation is a significant prognostic factor in stage 
sub-groups, 133 additional tumors were evaluated for this marker, thus increasing the 
statistical power for analysis of individual stages. As shown in Supplementary Table 2, 
there were no significant differences in the profile of clinicopathological features 
between the initial cohort of 246 cases and the additional 133 cases. The distribution of 
LINE-1 methylation was also identical between the two tumor cohorts (Supplementary 
Fig. 1). Combination of the two cohorts gave rise to 379 cases for analysis of the 
prognostic significance of LINE-1 methylation (stage IA, n=128; stage IB, n=76; stage II, 
n=34; stage III, n=129; stage IV, n=12). Survival information was available for 364 
patients and the median follow-up time was 44.5 months (range 2-158 months). Using a 
LINE-1 methylation cut-off value of 90% to stratify patients, a significant difference in 
prognosis was observed (P<0.001; Supplementary Fig. 2). 
Multivariate analysis showed that LINE-1 methylation remained significant as a 
prognostic factor (P=0.016) together with age (P=0.001), gender (P=0.001) and 
pathological stage (P<0.0001). In sub-group analysis of stage IA cases, survival was 
significantly worse for patients with LINE-1 hypomethylation (P=0.018; Fig. 3A). Of the 
126 stage IA patients, 91 were treated with surgery alone and 35 received adjuvant 
treatment that comprised VP16 + OK432 (n=23), OK432 (n=1), NK421 (n=5) or UFT 
(n=6). Patients who did or did not receive adjuvant chemotherapy showed no difference 
in LINE-1 methylation.  
Multivariate analysis of stage IA patients that included the variables of age, gender, 
smoking history, tumor size, histological type and post-operative therapy (with or 
without adjuvant treatment) revealed that LINE-1 methylation was the only significant 
prognostic factor (P=0.026; Table 3). Sub-group analysis failed to show prognostic value 
for LINE-1 methylation in all other NSCLC disease stages (Fig. 3B, C and D). 
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The prognostic significance of LINE-1 methylation in the initial 235 cases and in the 
additional 129 cases is shown separately and for each disease stage in Supplementary 
Fig. 3. The survival curves for the two cohorts were similar for stage IA and III patients 
(Supplementary Fig. 3B and E) but not for stage IB and II patients (Supplementary Fig. 
3C and D), probably due to the small number of patients in each group. 
Loss of Heterozygosity and LINE-1 methylation  
To investigate the molecular basis for the association between LINE-1 methylation and 
patient prognosis, LOH status was analyzed in 51 randomly selected tumors. 
Microsatellite analysis of the matching normal tissues showed that 30, 45 and 46 of the 
51 cases were heterozygous for the D5S346, D9S942 and TP53 markers, respectively, 
and therefore suitable for LOH analysis at these loci. All heterozygous cases were 
suitable for the evaluation of tumor LOH status except 3 that showed unstable allelic 
peaks at D9S942 indicating presence of the microsatellite instability phenotype. LOH 
was observed in 13/30 (43.3%), 22/42 (52.4%) and 26/46 (56.5%) tumors at D5S346, 
D9S942 and TP53, respectively. Representative results of the LOH analysis are shown 
in Supplementary Fig. 4A. Tumors showing LOH at one or more loci were considered to 
be LOH+. Using this criterion, 36 were LOH+ and 15 were LOH-. The median LINE-1 
methylation level in LOH+ tumors was significantly lower (61.7%, range 20.8-96.6%) 
than in LOH- tumors (84.9%, range 47.4-97.4; P=0.004; Supplementary Fig. 4B). This 
result supports the hypothesis that LINE-1 hypomethylation causes chromosomal 
instability through activation of its transposition, resulting in the accumulation of 
genetic abnormalities and hence poor prognosis in these patients. 
 
Discussion 
In this study we explored the prognostic significance of gene promoter and global 
methylation in tumor DNA from NSCLC patients. APC, CDH13 and RASSF1 were 
analyzed for promoter methylation and LINE-1 methylation was assessed as a 
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surrogate marker of global methylation. Both univariate and multivariate analyses of 
the initial cohort of 234 cases suggested that APC and LINE-1 methylation were 
promising prognostic factors in NSCLC. Since APC and LINE-1 methylation were also 
associated with pathological stage (Table 1), it was unclear from the study of this initial 
cohort whether they were independent prognostic factors. APC methylation showed no 
prognostic significance in sub-group analysis of each stage, while LINE-1 methylation 
showed marginal significance in stage IA and IB cases only. These initial results 
prompted us to further investigate LINE-1 methylation as a candidate prognostic factor 
in a larger series of tumors. Sub-group analysis of a larger cohort of 379 cases 
demonstrated that LINE-1 methylation was an independent prognostic factor in stage 
IA NSCLC (Fig. 3A and Table 3). Even for patients with early stage disease, the 
prognosis of NSCLC is relatively poor. Therefore, accurate prediction of the likely 
outcome of stage IA patients is very important for their post-operative management, 
including decisions on the use of adjuvant chemotherapy and the frequency of follow-up 
examination. The current results on the prognostic significance of LINE-1 methylation 
should be validated in prospective, large-scale clinical studies of NSCLC. 
Although LINE-1 has been used to assess global methylation in several cancer types 
(39-41), to our knowledge only one study of LINE-1 methylation in lung cancer has so 
far been reported (42). LINE-1 methylation was lower in NSCLC tissues compared to 
adjacent normal tissues, consistent with observations in other malignancies such as 
colorectal cancer (27), leukemia (43) and ovarian cancer (44). These results indicate that 
LINE-1 hypomethylation is a common event in a variety of cancer types and reflects 
global hypomethylation of tumor DNA. Similar to the present study of NSCLC, previous 
workers have reported that LINE-1 hypomethylation was associated with poor 
prognosis in colorectal cancer (22), leukemia (20) and ovarian cancer (21) patients. This 
is despite the use of different methods to measure methylation level. Preliminary work 
from our group using the same analytical method as in the current study also found 
that LINE-1 hypomethylation was a marker of poor prognosis in colorectal cancer (45). 
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Together, these results suggest that LINE-1 hypomethylation may have clinical 
application as a prognostic factor in a variety of malignancies. 
The mechanism by which LINE-1 methylation is associated with patient prognosis 
may be linked to the function of LINE-1 sequence as a retroposon. The LINE-1 sequence 
is 6kb in length and contains a 5’ UTR, two open reading frames and a 3’ UTR (46). The 
5’ UTR has internal promoter activity, while the second open reading frame encodes 
domains of nuclease and reverse transcriptase activities that are necessary for 
transposition (47, 48). Increased expression of LINE-1 following hypomethylation may 
be associated with chromosomal breaks via an increase in nuclease activity. This could 
result in chromosomal instability and lead to a variety of alterations such as deletion, 
amplification and translocation. Chromosomal instability is a characteristic phenotype 
of more aggressive cancers, suggesting that LINE-1 hypomethylation and subsequent 
expression are associated with more aggressive tumors and worse patient prognosis. In 
support of this hypothesis, LINE-1 hypomethylation in human primary cancer has been 
linked to genomic instability as observed by frequent LOH (42, 49). Our study also 
found that tumors showing frequent LOH at the D5S346, D9S942 and TP53 loci have 
significantly lower LINE-1 methylation compared to tumors without LOH. 
Investigation of the mechanisms that underlie LINE-1 expression and chromosomal 
breaks may be of great importance in controlling the progression of tumors with LINE-1 
hypomethylation. 
We previously reported that p16 methylation was a prognostic factor in 246 NSCLC 
cases studied here as the initial cohort (16). However, in the present study CDH13 
methylation showed no prognostic significance with any of the cut-off values, while the 
prognostic significance of RASSF1 methylation was lost in multivariate analysis. APC 
methylation remained significant in multivariate analysis but showed no clear 
association with patient outcome in any of the pathological stage subgroups. p16 
methylation on the other hand was associated with patient prognosis in stage IA disease 
(16). These results suggest that p16 is the most promising candidate amongst the 
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promoter methylation markers. A previous study reported that a combination of p16 
and CDH13 methylation gave promising results for the prediction of outcome in stage I 
NSCLC patients (17). Combinations of different gene promoters in the present study 
may also have resulted in stronger prognostic value than individual methylation 
markers. However, multiple comparisons can lead to false-positive results by chance 
and therefore we did not explore combinations of markers. This should be analyzed 
prospectively using fewer markers to avoid the chance of false-positive results. In this 
regard, the study of p16 and LINE-1 methylation could be of great interest. 
In conclusion, we have shown that LINE-1 methylation is significantly associated 
with patient prognosis in stage IA NSCLC. Lung cancer is a leading cause of 
cancer-related death and has poor prognosis even at early stages of disease. Hence, the 
ability to accurately predict the prognosis of patients with stage IA disease should 
improve strategies for deciding upon post-operative treatments and follow-up 
examinations. Further validation of the clinical significance of LINE-1 methylation as a 
prognostic marker in early stage NSCLC would appear warranted. 
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Figure 1. DNA methylation levels in normal and tumor lung tissues from patients with 
NSCLC. T, tumor tissue; N, normal tissue. Significant differences in the methylation 
level of CDH13 (P<0.0001), RASSF1 (P<0.0001) and LINE-1 (P<0.0001) were observed 
between tumor and normal tissues, but no difference was seen for APC methylation 
(P=0.15). 
 
Figure 2. Left panel, Correlations between the cut-off value used for stratification and 
the P-value from Log-rank test. The region below the dotted line indicates statistical 
significance (P<0.05). Right panel, Cumulative survival curves were constructed by the 
Kaplan-Meier method using cut-off values that showed the most significant prognostic 
difference between hypomethylated and hypermethylated tumor groups. The broken 
line indicates patients with hypomethylation and the solid line indicates patients with 
hypermethylation. 
 
Figure 3. Cumulative survival curves were constructed for stage IA (A), stage IB (B), 
stage II (C) and stage III patients (D) by the Kaplan-Meier method. The broken line 
indicates patients with LINE-1 hypomethylation (<90%) and the solid line indicates 
those with LINE-1 hypermethylation (≥90%). 
 
Supplementary Figure 1. LINE-1 methylation levels in lung tumor tissues from the 
initial cohort of 246 cases and the additional cohort of 133 cases. 
 
Supplementary Figure 2. Cumulative survival curves were constructed for 364 cases by 
the Kaplan-Meier method. The broken line indicates patients with LINE-1 





Supplementary Figure 3. Cumulative survival curves were constructed for all (A), stage 
IA (B), stage IB (C), stage II (D) and stage III patients (E) by the Kaplan-Meier method 
for the initial cohort of 235 cases (Left panel) and for the additional cohort of 129 cases 
(Right panel). The broken line indicates patients with LINE-1 hypomethylation (<90%) 
and the solid line indicates patients with LINE-1 hypermethylation (≥90%). 
 
Supplementary Figure 4. Correlation between LOH status and LINE-1 methylation in 
the tumor tissue of NSCLC patients. A, Representative case of LOH analysis using 
ABI-PRISM 310 Sequence Detection System and GeneMapper software. B, The LINE-1 
methylation level was significantly lower in tumors with LOH+ compared to those with 
LOH- (P=0.004).
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Table 1. Methylation levels in relation to clinicopathological features of NSCLC 
 n APC CDH13 RASSF1 LINE-1
Total 246 2.54 0.00 4.86 83.52
Age  
≤65 yrs 125 2.35 0.00 2.43* 85.64*
>65 yrs 121 2.81 0.00 14.72 82.00
Gender  
Male 154 2.12 0.00 4.62 74.20***
Female 92 3.20 0.69 5.33 87.78
Smoking  
No 83 3.19 0.67 6.36 87.57***
Yes 148 2.42 0.00 5.08 74.93
Unknown 15  
Histology  
Adeno 152 3.20* 0.83 8.60 87.93***
Squamous 87 1.59 0.00 1.85 64.17
Large 3 7.54 3.44 0.00 92.01
Other 4 4.18 3.19 6.88 77.87
Stage  
IA 88 3.18 0.00 3.25 87.71**
IB 52 2.04 0.00 9.79 74.70
II 20 1.95 0.00 11.26 83.33
III+IV 86 2.85 0.47 6.71 80.17
 
n, number of patients 
Median values are shown for promoter methylation (PMR) and LINE-1 methylation (%). 
∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001 
Data showing the median, 25th–75th percentile range and P-value is available in the 
Supplementary Tables 1.
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Table 2. Multivariate analysis for the prognostic significance of clinicopathological 
factors and DNA methylation in NSCLC
 Odds ratio (95%CI) P-value 
Older patients§ 2.03  (1.37-3.00) 0.0004 
Male 2.96  (1.58-5.55) 0.0007 
Smoker 1.08  (0.57-2.02) 0.82 
Histological type: adenocarcinoma† 1.38  (0.86-2.20) 0.19 
Pathological stage: stage I‡ 0.15  (0.10-0.24) <0.0001 
LINE-1 hypomethylation* 1.92  (1.16-3.18) 0.011 
APC hypermethylation** 1.65  (1.02-2.67) 0.040 
RASSF1 hypermethylation*** 0.88  (0.52-1.47) 0.62 
 
§Age: older (>65 yrs) vs younger (≤65 yrs) patients 
†Histological type: adenocarcinoma vs other types  
‡Pathological stage: stage I vs II/III/IV 
*LINE-1: hypomethylation vs hypermethylation using a cut-off value of 90%. 
**APC: hypermethylated vs hypomethylated using a cut-off value of 15 PMR. 
***RASSF1: hypermethylated vs hypomethylated using a cut-off value of 65 PMR.
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Table 3. Multivariate analysis for the prognostic significance of clinicopathological 
variables and LINE-1 methylation in stage IA NSCLC patients 
 
 Odds ratio (95%CI) P-value 
Older patients§ 0.90  (0.41-1.99) 0.80 
Male 1.29  (0.30-5.60) 0.73 
Smoker 1.97  (0.41-9.51) 0.40 
Tumor size: over 2cm‡ 0.76  (0.35-1.64) 0.49 
Histological type: adenocarcinoma† 1.11  (0.47-2.59) 0.82 
Adjuvant therapy: surgery alone 1.38  (0.56-3.43) 0.49 
LINE-1 hypomethylation* 3.45  (1.16-10.30) 0.026 
 
§Age: older (>65 yrs) vs younger (≤65 yrs) patients 
‡Tumor size: larger than 2.0cm vs no larger than 2.0cm 
†Histological type: adenocarcinoma vs other types 
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Supplementary Table 1. Methylation levels in relation to clinicopathological features of NSCLC 
 
 APC CDH13 RASSF1 LINE-1 
 n methylation P -value methylation P -value methylation P -value methylation P-value 
Total 246 2.54  0.00  4.86  83.52 
Age 
≤65 yrs 125 2.35 (0.33-12.63) 0.44 0.00 (0.00-8.53) 0.87 2.43 (0.00-26.57) 0.030 85.64 (69.37-92.01) 0.049
>65 yrs 121 2.81 (0.83-12.67)  0.00 (0.00-7.57)  14.72 (0.00-40.09)  82.00 (62.69-88.93) 
Gender 
Male 154 2.12 (0.38-10.61) 0.17 0.00 (0.00-7.04) 0.36 4.62 (0.00-46.40) 0.75 74.20 (57.48-88.80) <0.0001 
Female 92 3.20 (0.59-17.86)  0.69 (0.00-10.80)  5.33 (0.00-26.88)  87.78 (82.93-93.25) 
Smoking 
No 83 3.19 (0.52-16.88) 0.52 0.67 (0.00-9.42) 0.22 6.36 (0.00-23.54) 0.85 87.57 (82.34-93.23) <0.0001 
Yes 148 2.42 (0.45-11.48)  0.00 (0.00-6.21)  5.08 (0.00-43.24)  74.93 (59.06-88.77) 
Unknown 15 
Histology 
Adeno 152 3.20 (0.62-18.11) 0.011 0.83 (0.00-11.87) 0.63 8.60 (0.00-45.95) 0.57 87.93 (80.62-92.67) <0.0001 
Squamous 87 1.59 (0.33-3.73)  0.00 (0.00-4.90)  1.85 (0.00-29.27)  64.17 (48.79-78.80) 
Large 3 7.54 (4.58-81.99)  3.44 (1.72-6.14)  0.00 (0.00-308.65)  92.01 (74.75-93.35) 
Other 4 4.18 (0.43-15.84)  3.19 (0.44-5.82)  6.88 (3.06-15.14)  77.87 (66.67-83.76) 
Stage 
IA 88 3.18 (0.59-12.31) 0.97 0.00 (0.00-7.89) 0.86 3.25 (0.00-20.73) 0.20 87.71 (77.51-92.38) 0.0080 
IB 52 2.04 (0.68-5.37)  0.00 (0.00-7.40)  9.79 (0.25-48.42)  74.70 (58.11-87.86) 
II 20 1.95 (0.45-18.41)  0.00 (0.00-6.13)  11.26 (0.76-32.62)  83.33 (60.89-89.96) 
III+IV 86 2.85 (0.38-18.31)  0.47 (0.00-11.56)  6.71 (0.00-61.91)  80.17 (63.10-90.65) 
n, number of patients 
Each methylation was expressed as median (range of 25 and 75 percentile values). 
 
Supplementary Table 2. Clinicopathological profiles of the initial cohort of 246 cases and 
the additional cohort of 133 cases. 
 Initial cases Additional cases Chi-squared test
Total 246 133
Age  
≤65 125 62 p=0.50
>65 121 71
Gender  
Male 154 94 p=0.14
Female 92 39
Smoking  
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